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Gabapentin (GBP) (C9H17NO2), with the tradename Neurontin, is a new antiepileptic drug that 
was introduced by Park Davis Company in 1993 for 
adjunctive therapy of partial and second generalized 
seizures. Also, GBP was used as monotherapy in epilepsy, 
relief of neuropathic pain, prophylaxis of migraine, and 
for relief of post-dural puncture headache. Furthermore, 
there is some evidence that GBP has some beneficial 
effect in people with learning disabilities, that GBP 
is useful in the treatment of generalized vulvodynia, 
unprovoked. The wide range of action on the CNS of 
this newer antiepileptic drug may serve not only for 
clinical seizure suppression, but also for neuroprotection. 
Gabapentin is very water-soluble, and the half-life of 
GBP in humans is 5-7 hours and daily dosages range 
from 900-2,400 mg in adults. Lack of appreciable 
metabolism, no drug interaction in the body, rapid 
glomerular filtration rate, and good tolerance of this 
drug are reasons for its extensive usage. Furthermore, 
there is a little information on the teratogenic effects 
of GBP. Low molecular weight and no binding to the 
plasma proteins, probably causes this drug to transfer 
from the placental membrane. Some studies on rodents 
have shown that oral consumption of this drug (1000­
3000 mg/kg per day) during the organogenesis period 
causes delayed ossification of several bones in the skull, 
vertebrate, and upper and lower limbs.1 Another report 
showed that consumption of GBP during pregnancy can 
cause hydronephrosis and hydroureter in rat fetuses.2 
Although, Montouris,3 on the basis of prospective 
and retrospective data of 51 fetuses, including 3 twin 
gestations, collected from 39 women with epilepsy 
and other disorders exposed to GBP during pregnancy 
showed that GBP exposure during pregnancy did not 
lead to an increased risk for adverse maternal and fetal 
events.3 Of course it was noticed that due to the small 
number of patients examined in this study, additional 
data from more pregnancies and outcomes are needed. 
Clearly, the possible long-term effects on reproductive 
health and pregnancy outcome requires careful attention 
when antiepileptic drug therapy is being considered 
for a patient with childbearing potential. For these 
findings, this research was carried out to determine the 
teratogenic effects of GBP on limb and neural tube 
formation when consumed during implantation and 
neurulation in mice. 
This study was carried out on adult female and 
mature male BALB/c mice, aged 7-8 weeks old virgin, 
and weighing 28-30 gram in Birjand University of 
Medical Sciences, Birjand, Iran during 2005. The 
males were part of the animal house breeding stock 
with confirmed mating experience. Dry food pellets 
and water were provided ad libitum with animal house 
conditions maintained at 20.1-21.2oC, 65.5-65.8% 
relative humidity, and a 12 h:12 h photoperiod (lights on 
0700 to 1900 hours). Approval for this study was gained 
from the Birjand University of Medical Sciences Animal 
Care and Ethics Committee. Two females were caged 
with a male of the same strain overnight. The presence 
of vaginal plug the following morning confirmed that 
mating had taken place and was designated as day 0 of 
pregnancy (gestation day 0: GD 0). Females that did 
not mate within 2 estrus cycles were excluded from the 
study. Thirty pregnant mice were randomly divided 
into 2 experimental groups (10 mice in each group) 
receiving 20 mg/kg/day GBP in experimental group I, 
and 26 mg/kg/day GBP in experimental group II and, 
and one control group (10 mice) that received normal 
saline. These doses of GBP were the routine doses used 
for the treatment of patients with 70 kg average weight. 
The injections were carried out intraperitoneally from 
GD 1 to GD 10. Gabapentin powder was obtained 
from a 100 mg capsule from Pharma Science Inc., from 
Montreal, Canada. Dilution was carried out by normal 
saline. On GD 18, the pregnant mice were sacrificed 
under ether anesthesia and the uterus was opened and 
the umbilical cord cut close to the fetus, each fetus and 
placenta was then weighed. Each fetus was assigned a 
number according to its position in the uterine horn, 
starting with number one at the ovarian end of the 
left uterine horn. Fetuses were assessed as either alive 
or dead and any resorptions noted, live fetuses were 
then euthanized by hypothermia. All live fetuses were 
measured and examined externally for malformations 
or deviations from normal growth. Also, each of the 
fetuses was weighed by sensitive electronic measurement 
serrations, GT 210 Ohaus Co., NJ, USA and observed 
by stereo research Microscope, Olympus SZX, Tokyo, 
Japan. 
Differences in body weight between the control 
and treatment groups were analyzed using a One-Way 
ANOVA with Tukey post-test. Resorbed implantation 
frequency was tested using a χ2 analysis. A P-value of 
less than 0.05 was considered significant. The data were 
analyzed with SPSS (version 11.5). 
Disclosure. This study was not supported/financed by 
the drug manufacturer. This study was financed by the 
Birjand University of Medical Sciences, Birjand, Iran. 
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Fetal observations. Mean±SD of weight of fetuses 
were 0.82±0.1 in the control group, 0.78±0.08 in group 
I, and 0.77±0.06 in group 2. Mean±SD of weight of 
fetuses in the experimental groups was significantly 
lower than control group (p=0.001). Also, a significant 
increase (p=0.01) in resorbed fetuses was observed in 
the experimental groups as compared with the fetuses 
in the control group. No malformation was observed in 
the control group. 
Fetal malformations in 20 mg/kg/day GBP 
experimental group (group I). In this group, out of the 
130 fetuses, 8 fetuses (6.15%) had birth defects, 4.6% of 
birth defects were limb anomalies. Neural tube defects 
(NTDs) (primarily cystica spina bifida in the thoracic 
region) were observed in 1.5% of fetuses. 
Fetal malformations in 26 mg/kg/day GBP group 
(group II). In this group, out of the 110 fetuses, 12 
(10.9%) of them had birth defects, 8.2% of birth 
defects were limb anomalies, such as upper and lower 
limb malrotation and micromelia (Figure 1). Neural 
tube defects were observed in 2.7% of the fetuses. 
The high incidence of limb defects in fetuses of the 2 
experimental groups was significant as compared with 
the control group. The incidence of NTDs in the 
fetuses of the 2 experimental groups was not significant 
as compared with fetuses in the control group. 
This investigation showed that consumption of 
GBP during the implantation and neurulation stages 
can cause severe limb malformations and NTDs in 
mice fetuses. In spite of expending data on the usage 
of GBP, there is little information on its teratogenic 
effects. The Federal Drug Administration has placed 
GBP in the C group category.1 This means that there 
is no evidence on the teratogenic effect of this drug 
on humans. Also, Montouris3 reported that GBP 
exposure during pregnancy did not lead to an increased 
risk for adverse maternal and fetal events. However, 
a little primary research on animals has shown that 
oral consumption of GBP with 1000-3000 mg/kg per 
Figure 1 - Fetus with upper (white arrow) and lower limb (black arrow) 
anomaly from experimental group II receiving 26mg/kg/day 
gabapentin). 
day during the organogenesis period can cause some 
teratogenic effects such as delayed ossification in some 
bones of the skull, vertebral column, and upper and 
lower limbs. Furthermore, this report determined other 
teratogenic effects of GBP such as hydronephrosis and 
hydroureter.2 Based on our research, we can classify 
the teratogenic effects of GBP into 2 categories: limb 
malformations and NTDs. In this study, we observed 
limb malformations such as: limb deformity and 
dislocation and pronounced shortening of limbs 
(meromelia) in the both experimental groups (20 and 
26 mg/kg/day GBP), although the severity of these 
defects was higher in group II, which received GBP 26 
mg/kg/day. These fetuses also, were smaller and paler 
than fetuses without anomaly. The above findings 
showed GBP can induce more serious limb defects 
than the previous reports mention.2 The second group 
of birth defects includes NTDs and the most common 
form was cystica spinal bifida in the thoracic region. 
These defects also, were seen in the both experimental 
groups. The occurrence of NTDs in experimental 
groups showed that GBP like the other antiepileptic 
drugs such as valproic acid and carbamazepine can affect
neural tube development, or can induce neural tube 
defects, although the incidence of these anomalies was 
not significant on comparing with the control group. 
Our findings on the NTDs in fetuses can be supported 
with a few case reports such as: birth of a newborn with 
cyclops and holoprosencephaly whose mother consumed 
GBP during pregnancy.1 Furthermore, recent studies 
have shown that components that affect the gamma­
aminobutyric acid (GABA) system can cause NTDs. 
For instance, research has reported that the teratogenic 
effect of valproic acid and benzodiazepine can be 
carried out by increasing the GABA concentration and 
increasing GABA receptors activity. By considering that 
GBP has structural similarities with GABA, and GBP 
is an analogue of GABA, therefore, the presentation of 
NTDs due to GBP consumption in pregnancy should 
be considered seriously. However, the exact mechanism 
of the teratogenic effects of GBP is not clear. However, 
the possible teratogenic effects of GBP may be due to 
influences in folic acid metabolism and decrease of folic 
acid level, changes in concentration of retinoic acid, 
especially 13 Cis-retinoic acids, alterations in GABA 
concentration. The other possible mechanism include 
induction of apoptosis, especially in neural tube cells, 
and production of the free radicals such as epoxide 
during metabolism of GBP.4,5 
Although this study showed that GBP cause limb 
and NTDs in an animal model, further investigations 
are needed to determine of exact mechanism and range 
of GBP teratogenicity. 
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